Indian Pharma Stocks Surge Following US Tariff Exemption

ndian pharmaceutical stocks experienced a significant rally, with shares jumping up to 14% after the US administration exempted pharmaceuticals from reciprocal tariffs. This exemption came amidst broader tariff measures imposed by the US on various countries, including India. The move highlights the critical role of generic medicines in global healthcare and economic stability.

Leading the charge were Gland Pharma and Aurobindo Pharma, which saw gains of 14.3% and 9.4%, respectively. Other major players like Lupin, Dr. Reddy’s Laboratories, and Sun Pharmaceuticals also recorded substantial increases. Analysts attribute this surge to the reassurance that Indian pharma companies will continue to enjoy strong export potential to the US, which is a key market for India’s generic medicines.

The exemption underscores the importance of cost-effective, life-saving drugs in public health and strengthens the bilateral trade relationship between India and the US. This development is seen as a positive step for the Indian pharmaceutical industry, which plays a vital role in ensuring affordable healthcare globally.